NOTHING CAN STOP WHAT IS COMING...NOTHING

Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are genetically modified G-protein-coupled receptors (GPCRs), that can be activated by a synthetic ligand which is otherwise inert at endogenous receptors. DREADDs can be expressed in cells in the central nervous system (CNS) and subsequently offer the opportunity for remote and reversible silencing or activation of the target cells when the synthetic ligand is systemically administered. In neuroscience, DREADDs have thus far shown to be useful tools for several areas of research and offer considerable potential for the development of gene therapy strategies for neurological disorders. However, in order to design a DREADD-based gene therapy, it is necessary to first evaluate the viral vector delivery methods utilised in the literature to deliver these chemogenetic tools. This review evaluates each of the prominent strategies currently utilised for DREADD delivery, discussing their respective advantages and limitations. We focus on adeno-associated virus (AAV)-based and lentivirus-based systems, and the manipulation of these through cell-type specific promoters and pseudotyping. Furthermore, we address how virally mediated DREADD delivery could be improved in order to make it a viable gene therapy strategy and thus expand its translational potential.

Obesity, a condition affecting more than one in three American adults, is associated with hypothalamic neuronal injury, inflammation, and gliosis- a process cha

Hundreds of hormones and ligands stimulate cyclic AMP (cAMP) signaling in different tissues through the activation of G-protein-coupled receptors (GPCRs). Although the functions and individual effe...

Europe PMC is an archive of life sciences journal literature.

Spinal cord injury (SCI) often damages, not only white matter axon tracts that transmits signals to and from the brain, but also the central gray matter, causin...

So you want to control neuronal activity, but should you choose chemogenetics or optogenetics? Read this article to see how these methods compare.

A central goal in understanding brain function is to link specific cell populations to behavioral outputs. In recent years, the selective targeting of specif...

In the past decade, emerging synthetic biology technologies such as chemogenetics have dramatically transformed how pharmacologists and systems biologists deconstruct the involvement of G protein–coupled receptors (GPCRs) in a myriad of physiological and translational settings. Here we highlight a specific chemogenetic application that extends the utility of the concept of RASSLs (receptors activated solely by synthetic ligands): We have dubbed it DREADDs (designer receptors exclusively activated by designer drugs). As we show in this review, DREADDs are now used ubiquitously to modulate GPCR activity noninvasively in vivo. Results from these studies have directly implicated GPCR signaling in a large number of therapeutically relevant contexts. We also highlight recent applications of DREADD technology that have illuminated GPCR signaling processes that control pathways relevant to the treatment of eating disorders, obesity, and obesity-associated metabolic abnormalities. Additionally, we provide an overview of the potential utility of chemogenetic technologies for transformative therapeutics.

In the Rh system, the "G antigen" (and its associated antibody) seems mysterious. You should understand both, especially in caring for pregnant patients.

Learn more about DREADD receptors and their ligands and actuators: CNO (clozapine n-oxide), perlapine, DREADD agonist 21 (Compound 21), J60, J52 and SalB (salvinorin B)

Cloud security startup Wiz has raised more than $120 million in a funding round led by customer relationship management (CRM) giant Salesforce, according to Bloomberg.

Benchling is a life science data management and collaboration platform.

Sell My Cell C Wiz in Used Condition for 💰 cash. Compare Trade in Price offered for working Cell C Wiz in UK. Find out How Much is My Cell C Wiz Worth to Sell.

Addgene's guide to using Chemogenetics plasmids in your lab for interrogation of neuronal activity.

Play and download songs by C-Wiz & Project Pat

WIZ AI Talkbot Software-as-a-Service (SaaS) Terms and Conditions THIS SOFTWARE AS A SERVICE AGREEMENT (“THE “AGREEMENT”) IS ENTERED INTO BETWEEN CUSTOMER AND WIZ. CUSTOMER AND WIZ AGREE THAT THE FOLLOWING TERMS AND CONDITIONS WILL APPLY TO THE SERVICES PROVIDED UNDER THIS AGREEMENT.1. Definition and Interpretation1.1 In this Agreement, the following words and expressions shall have […]

Designer receptors exclusively activated by designer drugs (DREADDs) are an advanced experimental tool that could potentially provide a novel approach to pain management. In particular, expression of an inhibitory (Gi-coupled) DREADD in nociceptors might enable ligand-dependent analgesia. To test this possibility, TRPV1-cre mice were used to restrict expression of Gi-DREADDs to predominantly C-fibers. Whereas baseline heat thresholds in both male and female mice expressing Gi-DREADD were normal, 1 mg/kg clozapine- N -oxide (CNO) produced a significant 3 h increase in heat threshold that returned to baseline by 5 h after injection. Consistent with these behavioral results, CNO decreased action potential firing in isolated sensory neurons from Gi-DREADD mice. Unexpectedly, however, the expression of Gi-DREADD in sensory neurons caused significant changes in voltage-gated Ca2+ and Na+ currents in the absence of CNO, as well as an increase in Na+ channel (NaV1.7) expression. Furthermore, CNO-independent excitatory and inhibitory second-messenger signaling was also altered in these mice, which was associated with a decrease in the analgesic effect of endogenous inhibitory G-protein-coupled receptor activation. These results highlight the potential of this exciting technology, but also its limitations, and that it is essential to identify the underlying mechanisms for any observed behavioral phenotypes. SIGNIFICANCE STATEMENT DREADD technology is a powerful tool enabling manipulation of activity and/or transmitter release from targeted cell populations. The purpose of this study was to determine whether inhibitory DREADDs in nociceptive afferents could be used to produce analgesia, and if so, how. DREADD activation produced a ligand-dependent analgesia to heat in vivo and a decrease in neuronal firing at the single-cell level. However, we observed that expression of Gi-DREADD also causes ligand-independent changes in ion channel activity and second-messenger signaling. These findings highlight both the potential and the limitations of this exciting technology as well as the necessity to identify the mechanisms underlying any observed phenotype.

From automated cannons that literally shred their target to pieces, to extremely agile missile systems, Close-In Weapon Systems are a vessel's last line of defense against anything hostile above the waterline that is danger close. Lasers will eventually take on the majority of this duty, but in the meantime let's…

VAMPIRE! VAMPIRE! VAMPIRE!When I was in the Navy, it was my job to push the button. I was a fire controlman and I worked on multiple weapons systems

Throwback Video of The Kid Icarus Project at the Tross. Come check em out this Sunday on the patio at 2:00 and don’t forget we are open everyday to go. . . Video Cred: Val Sutton

12 likes, 2 comments - primecenterforhealthequity on July 28, 2021: "Congrats to our Research Assistant Jianee Carrasco on her amazing poster at the 2021 APA Division 45 Research Conference this last weeken..."